DE69940923D1 - Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren - Google Patents
Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptorenInfo
- Publication number
- DE69940923D1 DE69940923D1 DE69940923T DE69940923T DE69940923D1 DE 69940923 D1 DE69940923 D1 DE 69940923D1 DE 69940923 T DE69940923 T DE 69940923T DE 69940923 T DE69940923 T DE 69940923T DE 69940923 D1 DE69940923 D1 DE 69940923D1
- Authority
- DE
- Germany
- Prior art keywords
- constitutatively
- endogenic
- activated
- protein coupled
- oral receptors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9487998P | 1998-07-31 | 1998-07-31 | |
| US10630098P | 1998-10-30 | 1998-10-30 | |
| US11090698P | 1998-12-04 | 1998-12-04 | |
| US12185199P | 1999-02-26 | 1999-02-26 | |
| PCT/US1999/017425 WO2000006597A2 (en) | 1998-07-31 | 1999-07-30 | Endogenous constitutively activated g protein-coupled orphan receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69940923D1 true DE69940923D1 (de) | 2009-07-09 |
Family
ID=27492754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69940923T Expired - Lifetime DE69940923D1 (de) | 1998-07-31 | 1999-07-30 | Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1095275B1 (enExample) |
| JP (1) | JP2002521681A (enExample) |
| CN (1) | CN1231762C (enExample) |
| AT (1) | ATE432472T1 (enExample) |
| AU (1) | AU751080B2 (enExample) |
| CA (1) | CA2338543C (enExample) |
| DE (1) | DE69940923D1 (enExample) |
| DK (1) | DK1095275T3 (enExample) |
| IL (1) | IL140858A0 (enExample) |
| MX (1) | MXPA01001176A (enExample) |
| NO (1) | NO20010509L (enExample) |
| NZ (1) | NZ509429A (enExample) |
| WO (1) | WO2000006597A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| MXPA02009902A (es) | 2000-04-07 | 2003-06-17 | Arena Pharm Inc | Receptores acoplados a proteina g, conocidos, activados constitutivamente, no endogenos. |
| AU2003218234A1 (en) * | 2002-03-15 | 2003-09-29 | Arena Pharmaceuticals, Inc. | Methods of expressing non-endogenous g protein coupled receptors in cells |
| AU2003219030A1 (en) * | 2002-03-22 | 2003-10-08 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21) |
| WO2004015422A2 (en) * | 2002-08-05 | 2004-02-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1) |
| EP1578798A1 (en) * | 2002-12-20 | 2005-09-28 | 7TM Pharma A/S | Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| WO2005095990A1 (en) * | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507518A (ja) * | 1995-06-07 | 1999-07-06 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｇ蛋白質とカップルしたレセプターのアゴニスト及びアンタゴニストの機能的バイオアッセイ |
| EP0862614A1 (en) * | 1995-09-20 | 1998-09-09 | Molecular Geriatrics Corporation | Yeast receptor and g-protein fusion protein |
| DK0965041T3 (da) * | 1997-04-14 | 2009-05-25 | Arena Pharm Inc | Fremgangsmåde til identifikation af modulatorer af celleoverflade-membranreceptorer, som kan anvendes til behandling af sygdomme |
-
1999
- 1999-07-30 CN CNB998122653A patent/CN1231762C/zh not_active Expired - Fee Related
- 1999-07-30 JP JP2000562393A patent/JP2002521681A/ja not_active Ceased
- 1999-07-30 DE DE69940923T patent/DE69940923D1/de not_active Expired - Lifetime
- 1999-07-30 DK DK99941990T patent/DK1095275T3/da active
- 1999-07-30 AU AU55459/99A patent/AU751080B2/en not_active Ceased
- 1999-07-30 MX MXPA01001176A patent/MXPA01001176A/es unknown
- 1999-07-30 EP EP99941990A patent/EP1095275B1/en not_active Expired - Lifetime
- 1999-07-30 AT AT99941990T patent/ATE432472T1/de not_active IP Right Cessation
- 1999-07-30 CA CA002338543A patent/CA2338543C/en not_active Expired - Fee Related
- 1999-07-30 IL IL14085899A patent/IL140858A0/xx unknown
- 1999-07-30 WO PCT/US1999/017425 patent/WO2000006597A2/en not_active Ceased
- 1999-07-30 NZ NZ509429A patent/NZ509429A/en not_active IP Right Cessation
-
2001
- 2001-01-30 NO NO20010509A patent/NO20010509L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE432472T1 (de) | 2009-06-15 |
| CA2338543A1 (en) | 2000-02-10 |
| NZ509429A (en) | 2002-06-28 |
| EP1095275A2 (en) | 2001-05-02 |
| WO2000006597A9 (en) | 2000-07-13 |
| WO2000006597A3 (en) | 2000-05-18 |
| DK1095275T3 (da) | 2009-09-28 |
| AU5545999A (en) | 2000-02-21 |
| NO20010509D0 (no) | 2001-01-30 |
| CN1231762C (zh) | 2005-12-14 |
| WO2000006597A2 (en) | 2000-02-10 |
| JP2002521681A (ja) | 2002-07-16 |
| CA2338543C (en) | 2009-12-29 |
| AU751080B2 (en) | 2002-08-08 |
| EP1095275B1 (en) | 2009-05-27 |
| CN1323396A (zh) | 2001-11-21 |
| MXPA01001176A (es) | 2005-07-25 |
| NO20010509L (no) | 2001-03-19 |
| IL140858A0 (en) | 2002-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1261322T3 (da) | Farmaceutiske sammensætninger omfattende en adenosinreceptoragonist eller antagonist | |
| DE69903953D1 (de) | 2-substituierte-1-piperidyl-benzimidazolverbindungen als orl1 rezeptor agonisten | |
| DE60120748D1 (de) | 3-substituierte oxindolderivate als beta-3-agonisten | |
| DK1199069T3 (da) | Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed | |
| DE69934241D1 (de) | Agonistische antikörper gegen tie2 | |
| BR0110079A (pt) | Combinação de compostos orgânicos | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| TR199801679T2 (xx) | Osteoporoz i�in birle�tirme terapisi. | |
| LU91758I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
| BR9206237A (pt) | Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1. | |
| EP1461061A4 (en) | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS | |
| DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
| BRPI0410884A (pt) | composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação | |
| BR0007864A (pt) | Composto, e, uso de um composto | |
| EA200300593A1 (ru) | Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора | |
| EE04141B1 (et) | 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga | |
| FI962969L (fi) | Indolijohdannaisia 5-HT1:n agonisteina | |
| BRPI0413676A (pt) | composto, e, composição farmacêutica | |
| BR0317229A (pt) | Composição e uso de agonista completo de alfa7nachr | |
| DE69940923D1 (de) | Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren | |
| BR0108454A (pt) | Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos | |
| CO5460266A1 (es) | Novedosos analogos de la somatostatina | |
| DE69941298D1 (de) | Radiomarkierte neurokinin-1 rezeptor antagonisten | |
| DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
| EA200500830A1 (ru) | Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |